Clinical Scorecard: FDA approves neladalkib for ALK-positive lung cancer
At a Glance
| Category | Detail |
|---|---|
| Condition | Locally advanced or metastatic ALK-positive non–small cell lung cancer (NSCLC) |
| Key Mechanisms | Neladalkib is an oral ALK tyrosine kinase inhibitor; the source does not describe its mechanism in further detail. |
| Target Population | Adults previously treated with alectinib as their only ALK TKI in the unresectable locally advanced or metastatic setting, or with at least 2 ALK TKIs and platinum-based chemotherapy. |
| Care Setting | Treatment of adults with locally advanced or metastatic ALK-positive NSCLC after prior targeted therapy. |
Key Highlights
- The FDA granted accelerated approval to neladalkib on November 17.
- In ALKOVE-1, confirmed overall response rate was 49% among 67 patients previously treated with alectinib as their only ALK TKI.
- In a separate group of 155 patients previously treated with at least 2 ALK TKIs and platinum-based chemotherapy, confirmed overall response rate was 32%.
- The trial was multicenter, single-arm, and open-label, with no randomized comparator group.
- Neladalkib is taken orally at 150 mg once daily, with or without food, until disease progression or unacceptable toxicity.
Guideline-Based Recommendations
Diagnosis
Management
Monitoring & Follow-up
- Safety warnings include hepatotoxicity, renal toxicity, ocular toxicity, elevated creatine phosphokinase levels, and embryo-fetal toxicity.
Risks
Patient & Prescribing Data
Adults with locally advanced or metastatic ALK-positive NSCLC previously treated either with alectinib as their only ALK TKI in the unresectable locally advanced or metastatic setting, or with at least 2 ALK TKIs and platinum-based chemotherapy.
In ALKOVE-1, response rates were 49% and 32% in the respective prior-treatment groups. Among responders, 76% and 69% maintained response for at least 6 months, and 52% and 51% maintained response for at least 12 months.
Clinical Best Practices
- Neladalkib is administered orally at 150 mg once daily, with or without food, until disease progression or unacceptable toxicity.
- Safety warnings include hepatotoxicity, renal toxicity, ocular toxicity, elevated creatine phosphokinase levels, and embryo-fetal toxicity.
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
